Recombinant Oncolytic Vaccinia Virus with TK Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses, such as vaccinia virus, face challenges in selectively targeting and effectively killing cancer cells while minimizing harm to normal cells, and there is a need for improved methods to enhance their therapeutic efficacy and safety.
Innovation Solution
A replication-competent, recombinant oncolytic vaccinia virus is developed, encoding a heterologous thymidine kinase (TK) polypeptide variant, which is engineered to be deficient in endogenous TK activity, allowing for enhanced specificity and sensitivity to antiviral drugs like ganciclovir, thereby selectively targeting and killing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a replication-competent oncolytic vaccinia virus is used to kill cancer cells, then therapeutic efficacy is improved, but toxicity to normal cells increases
Solution Approach 1:
The vaccinia virus is engineered with a localized modification: deletion of the endogenous TK gene (J2R) specifically in the virus, while normal cells retain their functional TK. This creates a local difference in TK activity between virus-infected cells and uninfected normal cells, allowing selective vulnerability of cancer cells to ganciclovir while protecting normal cells
Solution Approach 2:
The invention changes the TK activity parameter of the virus by deleting the J2R gene, creating a TK-deficient vaccinia virus. This parameter change (from TK-competent to TK-deficient) enables the virus to replicate in cancer cells without providing the TK enzyme that would activate ganciclovir, thereby allowing ganciclovir to selectively kill virus-infected cancer cells while sparing normal cells that have functional TK
2Duration of action of moving object
If endogenous TK activity is present in the vaccinia virus, then viral replication is maintained, but sensitivity to ganciclovir is reduced
Solution Approach 1:
The endogenous TK gene (J2R) is extracted or removed from the vaccinia virus genome, creating a TK-deficient virus. This extraction eliminates the source of TK activity within the virus, making the virus sensitive to ganciclovir while maintaining its ability to replicate in cells that provide complementary functions
3Measurement precision
If the vaccinia virus is engineered to be TK-deficient, then specificity for cancer cells is improved, but viral replication capability may be affected
Solution Approach 1:
The invention uses ganciclovir as an intermediary agent that mediates the selective killing of virus-infected cancer cells. The TK-deficient vaccinia virus serves as a vector that delivers the effect of ganciclovir sensitivity to cancer cells without directly providing TK activity, thereby achieving specificity through the intermediary drug rather than through viral enzymes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered vaccinia virus demonstrates increased specificity for cancer cells, reduced toxicity to normal cells, and improved therapeutic efficacy, as evidenced by significant cancer cell killing and tumor reduction in preclinical models, along with the potential for inducing durable anti-tumor immune responses.
Implementation Method 1
encoding a heterologous thymidine kinase (TK) polypeptide variant, which is engineered to be deficient in endogenous TK activity, allowing for enhanced specificity and sensitivity to antiviral drugs like ganciclovir
Data Source
AI summary
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.